-
Dr. Yao Zhu talks to Dr. Nguyen: Advances in Radiotherapy and Surgical Treatment of Prostate Cancer at ASCO-GU 2023
The 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) has concluded. During this conference, several studies related to early-stage/ localized prostate cancer radiotherapy or surgical treatment were presented as oral reports. Among them, the FORMULA-509 study presented by Dr. Paul L. Nguyen of the Dana-Farber Cancer Institute at Harvard Medical School…
-
AASLD Voice of China: Dr. Liang Peng’s Hepatitis B Research Highlights Safety and Efficacy of Antiviral Therapy for ‘Healthy’ Carriers
Editor’s Note: From November 10th to 14th, 2023, the annual international highlight event in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual…
-
Dr. Zhiren Chen: 3-year follow-up data from the START-FIT trial, showing an ORR of 67% for local advanced liver cancer patients
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. In recent years, with the continuous improvement of diagnosis and treatment, the misdiagnosis rate and mortality of early-stage HCC have greatly decreased. However, many patients are already at an advanced stage when liver cancer is detected, making curative treatment impossible. For these…
-
APPLE 2023 | Application of Arterial Therapy in Early Hepatocellular Carcinoma: Korean Experience
With the advancement and innovation in surgical techniques, interventions, radiofrequency ablation, and other treatment methods, there are increasing treatments for early hepatocellular carcinoma. Curative treatments, including liver resection, liver transplantation, interventional treatment, ablative treatment, and radiotherapy, have all achieved satisfactory results. However, how to effectively and minimally invasively treat early hepatocellular carcinoma and manage it…
-
Dr. Linda Wong: Adjuvant Therapy Could Usher in a New Paradigm for Early-Stage Liver Cancer Treatment
Early-stage liver cancer can be cured with radical surgery. However, tumor recurrence remains the primary challenge affecting patients’ long-term survival. Currently, the five-year recurrence rate for early-stage liver cancer post-surgery is about 60%. Addressing this challenge and improving long-term survival for these patients is a pressing clinical issue. From July 6th to 8th, 2023, the…
-
ESMO Hot Review | Prof. Ying Fan: DB-04 Study Shows Survival Benefit and Sustained Efficacy of T-DXd Treatment
Editor’s Note: The mid-term analysis results of the DESTINY-Breast04 (DB-04) study were striking, quickly influencing international guidelines such as NCCN and ESMO, and obtaining approvals for indications related to HER2…
-
Lenvatinib, PD-1 inhibitors combined with radiotherapy safe and effective in treating hepatocellular carcinoma with portal vein tumor thrombus
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most patients are diagnosed at intermediate or advanced stages. The formation of portal vein tumor thrombus (PVTT) is a significant indicator of advanced HCC, with over half of late-stage HCC patients presenting with PVTT. Especially VP4 type (main portal vein), these patients…
-
Dr. Oi-Lin Ng: Heterogeneity of Liver Cancer and its Biological Markers
Liver cancer is the third leading cause of cancer death in China. In recent years, the application of targeted and immunotherapies has improved the survival of liver cancer patients. However, due to the high molecular heterogeneity of liver cancer, there is still a lack of biological markers for predicting clinical efficacy, and there is a…
Connecting Medical Expertise through Media